From 2022 onwards, manuscript published under COST LOBSTERPOT CA19138 need the following text:
Acknowledgement:
"This article/publication is based upon work from COST Action LOBSTERPOT CA19138 supported by COST (European Cooperation in Science and Technology)."
COST description:
"COST (European Cooperation in Science and Technology) is a funding agency for reseach and innovation networks. Our Actions help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation."
Weblink: www.cost.eu
For more info, please check the pdf: Acknowledging Cost funding.
2021
Christgen, M., Cserni, G., Floris, G., Marchio, C., Djerroudi, L., Kreipe, H., Derksen, P. W. B., and Vincent-Salomon, A. (2021)
Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors. Cancers. 13, 3695
Click here to download.
Pate, L., Desmedt, C., Metzger, O., Burgess Hutcheson, L., Turner, C., Freeney, S., and Oesterreich, S. (2021)
How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research. Cancers. 13, 3094
Click here to download.
Sflomos, G., Schipper, K., Koorman, T., Fitzpatrick, A., Oesterreich, S., V. Lee, A., Jonkers, J., Brunton, V.G., Christgen, M., Isacke, C., Derksen, P.W.B., Brisken C., on behalf of the ELBCC–LOBSTERPOT CA19138 Action. (2021)
Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions. Cancers. 13(21), 5396
Click here to download.
Journal Cancers special issue “Clinical, Pathological and Molecular Peculiarities of Lobular Breast Cancer”.
Special Issue Information
Invasive lobular breast cancer (ILC) represents the second most common histological subtype of invasive breast cancer. Large efforts in biomedical sciences and clinical research have yielded a wealth of data and insight into ILC development, diagnosis, progression, and responses to treatment. This knowledge has culminated in the awareness that ILC is a specific cancer type that should be recognized and treated as such.
There are nevertheless still important knowledge gaps with regard to this cancer type at the clinical, pathological, immune, and molecular level that need to be addressed. Implications of specific genomic alterations should be studied. The composition and role of the tumor microenvironment needs to be fully uncovered. Mechanisms explaining the long-term clinical dormancy observed in many of these ILC patients should be investigated. Additionally, adequate experimental models should be generated, properly described, and shared.
This Special Issue of Cancers therefore encompasses new research articles and timely reviews on all aspects of clinical, pathological, and molecular peculiarities of ILC.
Guest Editors:
Christine Desmedt, PhD
Patrick W. B. Derksen, PhD
Anne Vincent-Salomon, MD, PhD